[Use of extracts of Glycerrhiza glabra L. in the correction of some indices of local nonspecific defense in patients with protracted pulmonary pneumonia].
Results are presented of studies on local nonspecific defence in patients with protracted pneumonia in the bronchoalveolar lavage fluid (BALF) during the course of conventional therapy involving the use of T-activin and extractum Glycerrhiza glabra L. The course of conventional therapy has not been shown to be associated with a substantial normalization of cytosis in the BALF cell precipitate or augmentation of sIgA content of lysozyme. T-activin makes for a reduction in the content of mature neutrophilous granulocytes and for an increase in humoral factors of defence. Extractum Glycerrhiza glabra L. has been found to be superior to T-activin in diminishing neutrophilic granulocytes count, increase in the BALF content of macrophages, lysozyme, s IgA; it proved to be endowed with an antiphospholipase activity, which facts predetermine apperant efficacy of the drug with respect to the lung local defence system in those patients presenting with protracted pneumonia.
Karimov
M M
MM
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002908:Chronic Disease; D006801:Humans; D008264:Macrophages / Q000166:cytology / Q000187:drug effects; D009113:Muramidase / Q000737:chemistry / Q000187:drug effects; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D010455:Peptides / Q000627:therapeutic use; D010740:Phospholipases / Q000037:antagonists & inhibitors / Q000187:drug effects; D010936:Plant Extracts / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy*; D013949:Thymus Extracts / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D010455:Peptides; D010936:Plant Extracts; D013949:Thymus Extracts; C036191:T-activin; D010740:Phospholipases; D009113:Muramidase